Literature DB >> 15958080

Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.

B R Yacyshyn1, A Schievella, K L Sewell, J A Tami.   

Abstract

Serological profiles for anti-Saccharomyces cerevisiae antibodies (ASCA)/ perinuclear antineutrophil cytoplasmic antibodies (pANCA) and gene polymorphisms in tumour necrosis factor (TNF)-alpha and intercellular adhesion molecule-1 (ICAM-1) are associated with occurrence and/or outcome in Crohn's disease. The aim of the study was to characterize the ASCA/pANCA profile, soluble ICAM-1 expression and single nucleotide gene polymorphisms (SNPs) in TNF-alpha and ICAM-1 genes. Crohn's patients with moderate disease activity were enrolled in a clinical trial of Alicaforsen (ISIS 2302). Peripheral blood samples were collected prospectively for serum studies and for potential analysis of gene polymorphisms. A multivariate analysis was performed to compare treatment effect with the biomarkers studied. Serological testing for ASCA/pANCA was obtained for 257 patients at baseline: 37% were ASCA(+)/pANCA(-) (Crohn's pattern), 9% had both markers, 15% were ASCA(-)/pANCA(+) and 39% had neither marker. When the data were analysed by multiple regression analysis, a trend was found within the Alicaforsen-treated groups for greater rates of remission in the ASCA(+)/pANCA(-) subgroup versus all other serological profiles (25 versus 14%, P = 0.068), but not versus the placebo remission rate (18.8%). Gene polymorphisms were assessed in 64 patients, 21 from the placebo group. ICAM-1 assessment revealed no over-representation. However, three unique TNF-alpha SNPs were identified that correlated significantly with remission; sites 290 (P = 0.0253), -2735 (P = 0.0317) and -3090 (P = 0.0067). Although the overall clinical trial was negative, we have identified a trend towards clinical remission with Alicaforsen therapy in a subgroup of patients with Crohn's disease expressing ASCA(+)/pANCA(-). Furthermore, we have identified three TNF-alpha SNPs that may also predict a positive therapeutic outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958080      PMCID: PMC1809420          DOI: 10.1111/j.1365-2249.2005.02830.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

Review 1.  T-cell function and migration. Two sides of the same coin.

Authors:  U H von Andrian; C R Mackay
Journal:  N Engl J Med       Date:  2000-10-05       Impact factor: 91.245

2.  ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease.

Authors:  K D Taylor; S E Plevy; H Yang; C J Landers; M J Barry; J I Rotter; S R Targan
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

3.  Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population.

Authors:  J Matsuzawa; K Sugimura; Y Matsuda; M Takazoe; K Ishizuka; T Mochizuki; S S Seki; O Yoneyama; H Bannnai; K Suzuki; T Honma; H Asakura
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

4.  Intercellular adhesion molecule-1 gene polymorphisms in isolated polymyalgia rheumatica.

Authors:  Mahsa M Amoli; Emma Shelley; Derek L Mattey; Carlos Garcia-Porrua; Wendy Thomson; Ali H Hajeer; William E R Ollier; Miguel A Gonzalez-Gay
Journal:  J Rheumatol       Date:  2002-03       Impact factor: 4.666

5.  Intercellular adhesion molecule-1 gene polymorphisms in Behçet's Disease.

Authors:  L Boiardi; C Salvarani; B Casali; I Olivieri; G Ciancio; F Cantini; F Salvi; R Malatesta; M Govoni; F Trotta; D Filippini; G Paolazzi; D Nicoli; E Farnetti; L Macchioni
Journal:  J Rheumatol       Date:  2001-06       Impact factor: 4.666

6.  Polymorphisms of the ICAM-1 gene are associated with inflammatory bowel disease, regardless of the p-ANCA status.

Authors:  C Braun; R Zahn; K Martin; E Albert; C Folwaczny
Journal:  Clin Immunol       Date:  2001-12       Impact factor: 3.969

7.  Intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in Italian patients with rheumatoid arthritis.

Authors:  P Macchioni; L Boiardi; B Casali; D Nicoli; E Farnetti; C Salvarani
Journal:  Clin Exp Rheumatol       Date:  2000 Sep-Oct       Impact factor: 4.473

8.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

9.  Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.

Authors:  B R Yacyshyn; W Y Chey; J Goff; B Salzberg; R Baerg; A L Buchman; J Tami; R Yu; E Gibiansky; W R Shanahan
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

10.  Inflammatory bowel disease in children 5 years of age and younger.

Authors:  Petar Mamula; Grzegorz W Telega; Jonathan E Markowitz; Kurt A Brown; Pierre A Russo; David A Piccoli; Robert N Baldassano
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

View more
  2 in total

1.  Polymorphisms of the ICAM-1 gene are associated with biliary atresia.

Authors:  Cigdem Arikan; Afig Berdeli; Murat Kilic; Gokhan Tumgor; Rasit V Yagci; Sema Aydogdu
Journal:  Dig Dis Sci       Date:  2008-04-10       Impact factor: 3.199

Review 2.  The Role of the Lymphatic System in the Pathogenesis and Treatment of Inflammatory Bowel Disease.

Authors:  Dimitrios Nikolakis; Floris A E de Voogd; Maarten J Pruijt; Joep Grootjans; Marleen G van de Sande; Geert R D'Haens
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.